Retatrutide and Fatty Liver Disease (MASLD/MASH)
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD) affects an estimated 38% of the global population based on 2016-2019 data, up from 25% in 1990-2006. Its more severe form, MASH (formerly NASH), can progress to fibrosis, cirrhosis, and liver failure. There is no widely approved, highly effective pharmacotherapy for MASLD/MASH.
Retatrutide has produced some of the most striking liver fat reductions reported for any drug in development. A Phase 2 sub-study published in Nature Medicine showed liver fat reductions of up to 82.4% at the highest dose, with 86% of participants achieving normal liver fat levels. These results have generated significant interest in retatrutide as a potential treatment for fatty liver disease.
Retatrutide is an investigational drug that has not been approved by the FDA for any indication, including MASLD/MASH. A Phase 3 trial (TRIUMPH-MASLD) is ongoing.
The Phase 2 Liver Fat Sub-Study
Published in Nature Medicine in June 2024, this sub-study was conducted within the larger Phase 2 obesity trial (NCT04881760). It specifically evaluated retatrutide's effect on liver fat in participants with MASLD.
Study design
- 98 participants with MASLD and at least 10% liver fat (measured by MRI-PDFF)
- 48-week trial, randomized to retatrutide 1mg, 4mg, 8mg, 12mg, or placebo
- Primary endpoint: relative change in liver fat at 24 weeks
- Liver fat was measured using MRI-proton density fat fraction (MRI-PDFF), the gold standard non-invasive measurement
Liver fat reduction at 24 weeks
| Dose | Liver Fat Reduction | Achieved Normal (<5%) Liver Fat | p-value vs Placebo |
|---|---|---|---|
| Placebo | +0.3% | 0% | — |
| 1 mg | -42.9% | 27% | p<0.001 |
| 4 mg | -57.0% | 52% | p<0.001 |
| 8 mg | -81.4% | 79% | p<0.001 |
| 12 mg | -82.4% | 86% | p<0.001 |
All active doses achieved statistically significant liver fat reduction compared to placebo. The effect was strongly dose-dependent, with the 8mg and 12mg doses producing the most dramatic results.
Key findings
- Liver fat normalization: At the 12mg dose, 86% of participants achieved liver fat below 5% — the threshold for normal. This is a clinically meaningful endpoint because liver fat below 5% is associated with substantially lower risk of disease progression.
- Dose response: The reductions were clearly dose-dependent, with diminishing incremental benefit between 8mg and 12mg, suggesting near-maximal effect may be achieved at 8mg for liver fat specifically.
- Correlation with metabolic improvements: Liver fat reductions correlated with weight loss, reductions in abdominal fat, and improved insulin sensitivity.
- Placebo showed no change: The placebo group had a 0.3% increase in liver fat over the same period, underscoring that these reductions were drug-driven.
Why Retatrutide May Be Uniquely Effective for Liver Fat
Retatrutide's liver fat results are not simply a consequence of weight loss. While weight loss itself reduces liver fat, the glucagon receptor component of retatrutide likely contributes directly to hepatic fat reduction through several mechanisms:
Glucagon's direct liver effects
- Increased hepatic fatty acid oxidation — glucagon signals the liver to burn fat for energy rather than store it
- Decreased lipogenesis — glucagon reduces the liver's production of new fat
- Increased energy expenditure — glucagon promotes thermogenesis, shifting the body's overall energy balance
Why this matters for MASLD
Most GLP-1 drugs reduce liver fat to some degree through weight loss. But retatrutide's liver fat reductions appear disproportionately large relative to weight loss alone. The glucagon receptor activation provides a direct hepatic mechanism that other GLP-1-only or GLP-1/GIP drugs do not offer.
This is supported by the data: at the 8mg dose, 79% of participants achieved liver fat normalization — a rate that exceeds what has been reported for semaglutide or tirzepatide at similar levels of weight loss.
How Retatrutide Compares to Other Treatments
| Drug | Mechanism | Liver Fat Reduction | Context |
|---|---|---|---|
| Retatrutide 12mg | GLP-1 + GIP + Glucagon | -82.4% (24 wks) | Phase 2 sub-study |
| Tirzepatide 15mg | GLP-1 + GIP | ~37-53% (52 wks) | SYNERGY-NASH Phase 2 |
| Semaglutide 2.4mg | GLP-1 | ~30-40% | Various studies |
| Resmetirom (Rezdiffra) | THR-beta agonist | ~30-37% (52 wks) | Approved for MASH with fibrosis |
Note: Cross-trial comparisons have significant limitations due to different patient populations, study designs, liver fat measurement methods, and timepoints. These numbers are provided for context, not as direct comparisons.
Resmetirom (Rezdiffra), approved in 2024, is the first drug specifically approved for MASH with liver fibrosis. It works through a completely different mechanism (thyroid hormone receptor beta agonism). Retatrutide and resmetirom target different pathways, which raises the question of whether combination therapy could be explored in the future.
The TRIUMPH-MASLD Phase 3 Trial
Based on the strong Phase 2 results, Eli Lilly has initiated a dedicated Phase 3 trial evaluating retatrutide for MASLD/MASH. Key details:
- Trial name: TRIUMPH-MASLD
- Status: Ongoing (as of February 2026)
- Target population: Adults with MASLD/MASH
- Expected to evaluate: Liver fat reduction, histological improvement (liver biopsy endpoints), and potential fibrosis improvement
If the Phase 3 results confirm the Phase 2 findings, retatrutide could be filed for a MASLD/MASH indication in addition to obesity. This would be significant because effective, well-tolerated treatments for fatty liver disease remain a major unmet medical need.
Understanding MASLD and MASH
What is MASLD?
MASLD (metabolic dysfunction-associated steatotic liver disease) is the accumulation of excess fat in the liver in the presence of at least one metabolic risk factor (obesity, type 2 diabetes, dyslipidemia, or hypertension). It is the most common chronic liver disease worldwide, affecting approximately 38% of the global adult population.
What is MASH?
MASH (metabolic dysfunction-associated steatohepatitis) is the more severe form of MASLD where liver fat accumulation is accompanied by inflammation and liver cell damage. MASH can progress to:
- Fibrosis — scarring of the liver
- Cirrhosis — advanced, irreversible scarring that impairs liver function
- Hepatocellular carcinoma — liver cancer
- Liver failure — requiring transplantation
Why current treatment options are limited
Until recently, the primary treatment for MASLD/MASH was lifestyle modification — weight loss through diet and exercise. While effective, sustained weight loss is difficult for most patients. Resmetirom (Rezdiffra) was approved in 2024 for MASH with moderate to advanced fibrosis, but the treatment landscape remains limited. Retatrutide's strong liver fat data has generated interest as a potential option that addresses both obesity and liver fat simultaneously.
Frequently Asked Questions
Does retatrutide cure fatty liver disease?
The Phase 2 data showed that 86% of participants at the 12mg dose achieved normal liver fat levels (under 5%). However, "cure" is not the right framing — MASLD is a chronic condition linked to metabolic dysfunction, and liver fat would likely return if the drug were stopped (as is the case with weight regain after stopping GLP-1 drugs). Long-term treatment and sustained metabolic improvement are likely necessary to maintain benefits.
Is retatrutide approved for MASLD or MASH?
No. Retatrutide is not approved by the FDA for any indication. The Phase 2 liver fat data is promising, but Phase 3 confirmation is required. The TRIUMPH-MASLD trial is ongoing.
How does retatrutide reduce liver fat if it is a weight loss drug?
Retatrutide reduces liver fat through two mechanisms: indirect (through overall weight loss and improved metabolic health) and direct (through glucagon receptor activation, which signals the liver to burn stored fat and reduce new fat production). The combination of these mechanisms likely explains why retatrutide's liver fat reductions exceed what would be expected from weight loss alone.
Can I take retatrutide for fatty liver disease now?
No. The only way to receive retatrutide is through a clinical trial. Search for trials at ClinicalTrials.gov or LillyTrialGuide.com. If you have MASLD or MASH, talk to your doctor about currently available treatments and monitoring.
Sources
- Hartman, M.L., et al. (2024). Effects of retatrutide on liver fat in people with obesity and metabolic dysfunction-associated steatotic liver disease. Nature Medicine. DOI: 10.1038/s41591-024-03018-2
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- Younossi, Z.M., et al. (2023). The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology.
- ClinicalTrials.gov: NCT04881760
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you have been diagnosed with fatty liver disease (MASLD/MASH), work with your hepatologist or gastroenterologist to determine the best treatment approach using currently approved therapies.
This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.
Sources
- Phase 2 liver fat sub-study
Nature Medicine
- Phase 2 obesity trial
ClinicalTrials.gov
Related reading
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.
Retatrutide Clinical Trials & Results
Living tracker of all retatrutide trials — Phase 1 through the TRIUMPH Phase 3 program.
Retatrutide for Type 2 Diabetes
Retatrutide's Phase 2 T2D data showed HbA1c reductions of -2.02% and weight loss of -16.94% — with the TRANSCEND Phase 3 program underway.